ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NCYT Novacyt S.a.

61.00
6.00 (10.91%)
17 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Novacyt S.a. LSE:NCYT London Ordinary Share FR0010397232 EUR1/15TH (CDI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  6.00 10.91% 61.00 60.00 63.00 61.00 56.00 56.00 308,834 16:28:57
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
In Vitro,in Vivo Diagnostics 22.49M -25.73M - N/A 0

Novacyt S.A. PLACED IN TECHNOLOGY FAST 500 EMEA AWARDS

02/01/2018 7:00am

RNS Non-Regulatory


TIDMNCYT

Novacyt S.A.

02 January 2018

FOR THE THIRD YEAR RUNNING NOVACYT IS PLACED IN THE TECHNOLOGY FAST 500 EMEA AWARDS

Paris, France and Cambridge, UK - 2 January 2018 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has been ranked 135 in Deloitte's Technology Fast 500(TM) EMEA. The awards rank 500 Technology, Media and Telecommunications companies with the highest rate of growth in Europe, the Middle East and Africa (EMEA).

Novacyt has delivered strong revenue growth averaging 113% between 2013 and 2016. In 2016, the Group generated revenues of EUR11.1 million on a consolidated basis, representing annual growth of 25%, with a 55% gross profit margin, which was an increase of seven percentage points on the previous year.

Graham Mullis, Group CEO of Novacyt, commented:

"We are delighted to once again be placed in the Technology Fast 500 EMEA awards. This year Novacyt has received its highest ever ranking. The commitment to our three core strategic pillars is enabling us to deliver strong growth and puts us on a pathway to sustainable profitability.

"I would like to thank all our employees for their dedication and commitment in driving our business forward culminating in this achievement and I look forward to updating shareholders of our full year 2017 sales later this month."

- End -

About Deloitte Global's 2017 Technology Fast 500 EMEA program

Deloitte Global's Technology Fast 500(TM) EMEA program is an objective industry ranking focused on the technology ecosystem. It recognizes technology companies that have achieved the fastest rates of revenue growth in Europe, the Middle East, and Africa (EMEA) during the past four years. The program is supported by Deloitte Global's Technology Fast 50 initiatives, which rank high-growth technology companies by location or specifically defined geographic area, and are run by Deloitte Global's Technology, Media & Telecommunications (TMT) industry group. More information on the program is available at www.deloitte.com/fast500emea

Now in its seventeenth year, the Technology Fast 500 program in EMEA included over 18 countries, including Belgium, France, Finland, Germany, Italy, the Netherlands, Turkey and the UK. This year's winners were selected based on percentage fiscal-year revenue growth from 2013 to 2016.

Sponsors of Deloitte Global's 2017 Technology Fast 500 EMEA program are Euronext, a pan-European exchange that helps tech companies finance growth and innovative projects through the stock market; Oracle NetSuite, provider of cloud-based financials / Enterprise Resource Planning (ERP), HR and omnichannel commerce software that runs the business of companies in more than 100 countries; and Michael Page, recognized by clients and candidates the world over as the leading specialist consultancy in permanent recruitment, temporary staffing and interim management.

About Novacyt Group

The Novacyt Group is a rapidly growing, international diagnostics group with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NOVAPrep(R), and molecular platform, genesig(R), Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1223 395472

Stifel Nicolaus Europe Limited (Nominated Advisor and Joint Broker)

Jonathan Senior / Fred Walsh / Ben Maddison

+44 (0)20 7610 7600

International

Brett Pollard / Victoria Foster Mitchell

FTI Consulting

+44 (0)20 3727 1000

brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com

France

Arnaud de Cheffontaines / Astrid Villette

FTI Consulting

+33 (0)147 03 69 47 / +33 (0)147 03 69 51

arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASSDFMFFASESF

(END) Dow Jones Newswires

January 02, 2018 02:00 ET (07:00 GMT)

1 Year Novacyt Chart

1 Year Novacyt Chart

1 Month Novacyt Chart

1 Month Novacyt Chart

Your Recent History

Delayed Upgrade Clock